Skip to content

Study · Animal study (in vivo) · mouse · 2024

11 results

Mitochondria-derived peptide is an effective target for treating streptozotocin induced painful diabetic neuropathy through induction of activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator 1alpha -mediated mitochondrial biogenesis.

Xu L, Tang X, Yang L, Chang M, Xu Y, Chen Q, Lu C, Liu S, Jiang J

Molecular pain1 Jan 2024Cited by 5 (Europe PMC)

PMID38658141 (opens in a new tab)PMCIDPMC11113074 (opens in a new tab)DOI10.1177/17448069241252654 (opens in a new tab)PepBankPUB-38658141
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated mice, MOTS‑c treatment significantly reduced streptozotocin-induced weight loss.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment reduced the weight loss caused by streptozotocin.

    Peptide
    MOTS-c
    Outcome
    DecreaseSTZ-induced weight loss
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated mice, MOTS‑c treatment reduced the streptozotocin-induced elevation of blood glucose.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment lowered raised blood glucose.

    Peptide
    MOTS-c
    Outcome
    DecreaseSTZ-induced elevation of blood glucose
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated mice, MOTS‑c treatment improved mechanical allodynia.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment reduced pain from light touch.

    Peptide
    MOTS-c
    Outcome
    DecreaseMechanical allodynia
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated mice, MOTS‑c treatment improved thermal hyperalgesia.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment reduced heightened pain from heat.

    Peptide
    MOTS-c
    Outcome
    DecreaseThermal hyperalgesia
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In streptozotocin-treated mice, the improvements by MOTS‑c in weight loss, blood glucose, allodynia and hyperalgesia were blocked by the AMPK inhibitor dorsomorphin.

    In plain wordsIn diabetic-neuropathy mice, a drug that blocks AMPK stopped the benefits of MOTS‑c.

    Peptide
    MOTS-c
    Outcome
    No significant changeMOTS-c effects with AMPK inhibitor dorsomorphin
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Comparator
    Dorsomorphin
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with painful diabetic neuropathy, MOTS‑c treatment increased AMPK alpha 1/2 phosphorylation in the lumbar spinal cord.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment raised AMPK activation in the lower spinal cord.

    Peptide
    MOTS-c
    Outcome
    IncreaseAMPK alpha 1/2 phosphorylation in lumbar spinal cord
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, MOTS-c treatment significantly enhanced AMPKα1/2 phosphorylation and PGC-1α expression in the lumbar spinal cord of PDN mice.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with painful diabetic neuropathy, MOTS‑c treatment increased PGC-1 alpha expression in the lumbar spinal cord.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c treatment raised PGC-1 alpha levels in the lower spinal cord.

    Peptide
    MOTS-c
    Outcome
    IncreasePGC-1 alpha expression in lumbar spinal cord
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, MOTS-c treatment significantly enhanced AMPKα1/2 phosphorylation and PGC-1α expression in the lumbar spinal cord of PDN mice.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with painful diabetic neuropathy, MOTS‑c restored mitochondrial biogenesis.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c restored the making of new mitochondria.

    Peptide
    MOTS-c
    Outcome
    IncreaseMitochondrial biogenesis
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistic studies indicated that MOTS-c significantly restored mitochondrial biogenesis, inhibited microglia activation, and decreased the production of pro-inflammatory factors, which contributed to the alleviation of pain.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice with painful diabetic neuropathy, MOTS‑c inhibited microglia activation.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c reduced activation of microglia, immune cells of the nervous system.

    Peptide
    MOTS-c
    Outcome
    DecreaseMicroglia activation
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistic studies indicated that MOTS-c significantly restored mitochondrial biogenesis, inhibited microglia activation, and decreased the production of pro-inflammatory factors, which contributed to the alleviation of pain.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with painful diabetic neuropathy, MOTS‑c decreased the production of pro-inflammatory factors.

    In plain wordsIn diabetic-neuropathy mice, MOTS‑c lowered the production of inflammation-promoting molecules.

    Peptide
    MOTS-c
    Outcome
    DecreasePro-inflammatory factor production
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistic studies indicated that MOTS-c significantly restored mitochondrial biogenesis, inhibited microglia activation, and decreased the production of pro-inflammatory factors, which contributed to the alleviation of pain.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 11AnimalEndogenous levelAnimal study (in vivo)Other

    In mice with streptozotocin-induced painful diabetic neuropathy, the body's own MOTS‑c in plasma and spinal dorsal horn was lower than in control animals.

    In plain wordsIn diabetic-neuropathy mice, the body's own MOTS‑c levels in plasma and spinal cord were lower than in control mice.

    Peptide
    MOTS-c
    Outcome
    DecreaseEndogenous MOTS-c in plasma and spinal dorsal horn
    Study

    mousen: not reported in source

    Streptozotocin-induced painful diabetic neuropathy
    Comparator
    Control animals
    Outcome group
    Mitochondrial function · Nervous system and cognition

    Source sentences

    Summary
    We found that endogenous MOTS-c levels in plasma and spinal dorsal horn were significantly lower in STZ-treated mice than in control animals.
    1 context sentence
    Summary · context
    This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.